Alert

CEL-SCI Corporation (CVM)

NYSE American: CVM · Real-Time Price · USD

1.47

-0.05 (-3.29%)

At close: Aug 12, 2026, 11:15 AM

-3.29% (1D)

Bid	1.45
Market Cap	25.61M
Revenue (ttm)	n/a
Net Income (ttm)	-22.7M
Beta	0.56
EPS (ttm)	-2.15
PE Ratio (ttm)	n/a
Forward PE	-0.23
P/B (ttm)	1.81
P/S (ttm)	n/a
Earnings Date	Feb 12, 2026

Ask	1.47
Volume	73,084
Avg. Volume (20D)	419,733
Open	1.51
Previous Close	1.52
Day's Range	1.45 - 1.54
52-Week Range	0.89 - 13.48
Analyst	Strong Buy
Price Target	12.5 (750.34%)
Dividends	n/a
Ex-Dividend Date	Aug 28, 1996

About CVM

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulat...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 8, 1983

Employees n/a

Stock Exchange NYSE American

Ticker Symbol CVM

Website https://cel-sci.com

Full Company Profile

Financial Performance

In 2025, CEL-SCI's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -25.41M, a decrease of -5.61%.

Financial Statements

Analyst Forecast

According to 2 analyst ratings, the average rating for CVM stock is "Strong Buy". The 12-month stock price forecast is 12.5, which is upside of 750.34% from the latest price.

Stock Forecasts